The utility of recruitment incentives in early Alzheimer's disease trials
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.14143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Marina Ritchie und 7 weiteren Autor:innen. Beteiligte Einrichtung: UC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Positron-Emission Tomography, Cognitive Dysfunction, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, BrightFocus Foundation.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Amid recent approvals, early Alzheimer's disease (AD) remains an active area of treatment development. METHODS We performed a conjoint experiment to compare preferences among 26 patients with mild cognitive impairment for four trial features including designs incorporating active aducanumab‐control (vs. placebo), returning tau positron emission tomography (PET) results (vs. no disclosure), remote study partner participation (vs. in person), and increased risk of brain swelling (vs. lower risk). We used a generalized estimating equation to model the utility of factor levels. RESULTS Returning tau PET results had the highest utility (est: 0.47; 95% confidence interval [CI]: 0.13, 0.81; P = 0.007); remote study partner participation showed a similar trend (est: 0.29; 95% CI: −0.05, 0.63; P = 0.097). Trials with active‐controlled design (est: 0.01; 95% CI: −0.33, 0.35; P = 0.956) did not demonstrate utility and higher risk of brain swelling had negative utility (est: −0.64; 95% CI: −0.99, −0.30; P < 0.001). DISCUSSION Returning additional biomarker results may increase willingness to enroll in early AD trials. Highlights We compared mild cognitive impairment participant preferences for four trial design features. Returning tau positron emission tomography results had the highest utility. Remote study partner participation showed a positive, albeit non‐significant, trend. No utility was observed for an active aducanumab‐control design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UC Irvine Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.
- Department of Neurobiology and Behavior, University of California, Irvine, California, USA.
- Department of Neurology, University of California, Irvine, California, USA.
- Department of Medicine, University of California, Irvine, California, USA.
- Department of Statistics, University of California, Irvine, California, USA.
- Department of Psychiatry and Human Behavior, University of California, Irvine, California, USA.
ORCID-Profile: Marina Ritchie
Förderung
- NIA NIH HHS
- BrightFocus Foundation
Zitieren
APA
Ritchie, M., Witbracht, M., Russ, E., Sajjadi, S. A., Thai, G. T., Tam, S., Gillen, D. L., & Grill, J. D. (2024). The utility of recruitment incentives in early Alzheimer's disease trials. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14143
Vancouver
Ritchie M, Witbracht M, Russ E, Sajjadi SA, Thai GT, Tam S, et al. The utility of recruitment incentives in early Alzheimer's disease trials. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14143
BibTeX
@article{Ritchie2024,
author = {Ritchie, Marina and Witbracht, Megan and Russ, Eunji and Sajjadi, S Ahmad and Thai, Gaby T and Tam, Steven and Gillen, Daniel L and Grill, Joshua D},
title = {The utility of recruitment incentives in early Alzheimer's disease trials},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.14143}
}
EUVIMED